LeonaBio
Yahoo Finance • 2 months ago
LeonaBio beats Q2 loss forecast as Phase 3 ELAINE-3 trial advances
Medical research ©rawpixel LeonaBio, Inc. (NASDAQ:LONA) reported a smaller-than-expected second-quarter loss on Monday as the clinical-stage biopharmaceutical company continued to advance its pivotal Phase 3 ELAINE-3 study of lasofoxifene... Full story
Yahoo Finance • 6 months ago
LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer
Management to be Joined by Two Clinical Leaders in the Breast Cancer Field Expected to Complete Enrollment in Ongoing ELAINE-3 Phase 3 Registrational Study of Lasofoxifene in Metastatic Breast Cancer in 4Q26 with Data Expected in 2H27 We... Full story
Yahoo Finance • 6 months ago
LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update
Acquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator (SERM), a Potential Multi-Billion Dollar Opportunity as Treatment Option for Breast Cancer Patients with ESR1-Mutations Received G... Full story